A Phase III, Double-blinded, Single Center, Randomized, Placebo Controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Single Intravenous Dose of Allogeneic Ischemia Tolerant Human Mesenchymal Bone Marrow Cells to Subjects With Acute Myocardial Infarction

Trial Profile

A Phase III, Double-blinded, Single Center, Randomized, Placebo Controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Single Intravenous Dose of Allogeneic Ischemia Tolerant Human Mesenchymal Bone Marrow Cells to Subjects With Acute Myocardial Infarction

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2016

At a glance

  • Drugs Ischemia-tolerant mesenchymal stem cells (Primary)
  • Indications Cardiomyopathies; Myocardial infarction; Myocardial reperfusion injury
  • Focus Adverse reactions; Registrational
  • Sponsors Altaco XXI
  • Most Recent Events

    • 13 Apr 2016 Status changed from recruiting to completed.
    • 25 Feb 2014 New trial record
    • 19 Feb 2014 Status changed from planning to recruiting based on information reported in a CardioCell media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top